<DOC>
	<DOCNO>NCT02447926</DOCNO>
	<brief_summary>Regulatory CD4+CD25+ T cell ( Treg ) derive thymus and/or periphery control immune responsiveness auto- allo-antigens . However , effort harness therapeutic potential isolate Tregs control graft rejection induce transplantation tolerance solid organ recipient . In order Tregs use clinical treatment , follow property necessary : ex vivo generation sufficient number cell , migration vivo sit antigenic reactivity , ability suppress rejection alloantigen-specific manner , survival/expansion infusion . The others demonstrate 1 ) feasibility expand Treg ex vivo , 2 ) ability cell down-regulate allogeneic immune response vitro , 3 ) efficacy Treg prevention allograft rejection animal model . In kidney transplant , investigator develop strategy ex vivo expansion naturally occur human Tregs ( nTregs ) leukapheresis product would allow clinical employment cellular therapy . The investigator also interested approach patient end stage liver disease ( ESLD ) undergo liver transplantation ( LT ) . Our central hypothesis alloreactive human nTreg suppressive action expand ex vivo ESLD patient ( proposal ) use prevent liver transplant rejection facilitate minimization withdrawal drug-based immunosuppression ( future proposal ) . This application define validate efficient method ex vivo expansion human CD4+CD25+CD127- FOXP3+nTregs cell ESLD . The investigator herein propose use leukapheresis product obtain patient ESLD refine optimize protocol expansion Tregs . Suppressive function expand cell assess use vitro assay alloreactivity ( mixed lymphocyte culture ) .</brief_summary>
	<brief_title>Procurement Leukapheresis Products From End Stage Liver Disease ( ESLD ) Patients Immunological Studies</brief_title>
	<detailed_description>Regulatory CD4+CD25+ T cell ( Treg ) derive thymus and/or periphery control immune responsiveness auto- allo-antigens . However , effort harness therapeutic potential isolate Tregs control graft rejection induce transplantation tolerance solid organ recipient . In order Tregs use clinical treatment , follow property necessary : ex vivo generation sufficient number cell , migration vivo sit antigenic reactivity , ability suppress rejection alloantigen-specific manner , survival/expansion infusion . We others demonstrate 1 ) feasibility expand Treg ex vivo , 2 ) ability cell down-regulate allogeneic immune response vitro , 3 ) efficacy Treg prevention allograft rejection animal model . In kidney transplant , develop strategy ex vivo expansion naturally occur human Tregs ( nTregs ) leukapheresis product would allow clinical employment cellular therapy . We also interested approach patient end stage liver disease ( ESLD ) undergo liver transplantation ( LT ) . Our central hypothesis alloreactive human nTreg suppressive action expand ex vivo ESLD patient ( proposal ) use prevent liver transplant rejection facilitate minimization withdrawal drug-based immunosuppression ( future proposal ) . This application define validate efficient method ex vivo expansion human CD4+CD25+CD127- FOXP3+nTregs cell ESLD . We herein propose use leukapheresis product obtain patient ESLD refine optimize protocol expansion Tregs . Suppressive function expand cell assess use vitro assay alloreactivity ( mixed lymphocyte culture ) .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<criteria>&gt; 18 year old , ESLD MELD &lt; 25 , No recent infection , hepatic decompensation , history HIV , weight &gt; 110 lb , platelet &gt; 50,000 , HGB &gt; 10 , prior organ transplant Patients ineligible liver transplant , patient understand study procedure conduct , subject meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>leukapheresis</keyword>
	<keyword>regulatory T cell</keyword>
	<keyword>liver transplantation</keyword>
</DOC>